Portal de Periódicos da CAPES

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs

2017; Oxford University Press; Volume: 216; Issue: 2 Linguagem: Inglês

10.1093/infdis/jix211

1537-6613

Helen W. Boucher, Paul G. Ambrose, Henry F. Chambers, Richard H. Ebright, Amanda Jezek, Barbara E. Murray, Jason G. Newland, Belinda Ostrowsky, John Rex,

Bacterial Identification and Susceptibility Testing

Despite progress in antimicrobial drug development, a critical need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria. Infections due to resistant gram-negative bacilli continue to cause unacceptable morbidity and mortality rates. Antibacterial agents have been historically studied in noninferiority clinical trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria. Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development. Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clinical trials and ultimately approval of critically needed new antibacterial agents.